OcuPro, a new device from Oculogica for testing impairment after cannabis use, was featured on Kare 11 News.
The device has gone through several design iterations already, according to Joel Sanderson, Oculogica’s chief technology officer. “We’re always exploring new technologies; improving ways to keep doing things better,” said Sanderson.…
Neuro-diagnostic company Oculogica today announced the launch of OcuPro, the fastest roadside cannabis test with immediate results, along with pilots planned with several police departments across the U.S. Officers administer the 45-second long test and receive an immediate indication of recent cannabis use and impairment.…
Sofia Fund portfolio company Oculogica signs on one of the largest neurology clinics in the U.S. to use its device.
This is a major innovation as CTE (chronic traumatic encephalopathy) is currently only diagnosed after death.
Oculogica’s patent enables expansion of its eye-tracking based technology to fulfill an unmet need in cannabis impairment detection
Sofia Fund portfolio company Oculogica receives $2M U.S. Army grant to develop wearable version of its technology
Keller Army Hospital at West Point, Children’s Hospital of Philadelphia, University of Wisconsin-Green Bay and AdHawk Microsystems will work with Oculogica to develop the wearable diagnostic.…
Chicago’s Midwest Orthopedics at Rush, one of the leading orthopedic clinics in the country, has adopted Oculogica’s EyeBOX® for concussion assessments. EyeBOX is the first FDA authorized diagnostic for concussion that does not require a baseline test.
Full press release here: https://www.prnewswire.…
Sofia Fund participates in recently closed $8M financing round announced by existing portfolio company, Oculogica. This round of funding will support further commercial distribution of the EyeBOX at Level I, II and III trauma centers nationwide, including additional units in use with the U.S.…
The American Medical Association (AMA) has confirmed the addition of a new Category 3 CPT Code, 0X17T, Eye movement analysis test without spatial calibration, allowing clinicians to appropriately report the services related exclusively to the Oculogica EyeBOX® exam.
Read the entire press release here:
https://www.biospace.com/article/releases/oculogica-announces-new-category-3-cpt-code-created-by-american-medical-association/…
Oculogica is highlighted in the Community section under the headline The Future of Healthcare “Tracking a person’s eye movements to diagnose brain injuries” with Dr. Uzma Samadani of Oculogica. Read the entire article here: